This Practice Note discusses the regulatory implications of the coronavirus (COVID-19) pandemic for the UK and European life sciences industry. It provides guidance as to the response of UK and EU regulators in the areas of clinical trials, inspections and the continuity of supply in medicinal products and medical devices, as well as the postponement of implementation of the Medical Devices Regulation (MDR). It also summarises key research and development (R&D) initiatives at a UK and EU level and European Commission guidance on the collection and transfusion of convalescent COVID-19 plasma.
If you expected to see yourself on this page, click here.
0330 161 1234